Paper61732
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein PS and 6 others. Ann Intern Med, 1976. Cited by 396 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Papers, record 61732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/61732
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bleomycin | Major topic |
| Cyclophosphamide | Major topic |
| Doxorubicin | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Prednisone | Major topic |
| Vincristine | Major topic |
| Adult | |
| Aged | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Lymphoma | |
| Male | |
| Middle Aged | |
| Remission, Spontaneous |
Source PubMed
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 396 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,664,000 | A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL. | Blood Adv | 2026 | https://conductscience.org/library/papers/42664000 | PubMed |
| 10,789,823 | Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. | Drug Saf | 2000 | https://conductscience.org/library/papers/10789823 | PubMed |
| 8,471,438 | Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8471438 | PubMed |
| 8,398,705 | Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8398705 | PubMed |
| 7,263,762 | Investigation results of a comparison made between the Kiel and Rappaport classifications of the non-Hodgkin's lymphomas, together with clinical data. | J Cancer Res Clin Oncol | 1981 | https://conductscience.org/library/papers/7263762 | PubMed |
| 7,105,385 | The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105385 | PubMed |
| 7,000,112 | Malignant lymphomas as tumours of the immune system. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7000112 | PubMed |
| 6,993,038 | Is there a role for radiotherapy in localized diffuse lymphomas? | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/6993038 | PubMed |
| 6,934,838 | DNA content of leukaemic cells in non-Hodgkin's lymphomas of low-grade malignancy. Flow-cytometric and morphological investigations with special regard to hyperploid cells. | Blut | 1980 | https://conductscience.org/library/papers/6934838 | PubMed |
| 6,878,096 | The need for prophylactic treatment to the central nervous system in patients with aggressive non-Hodgkin's lymphoma. | Postgrad Med J | 1983 | https://conductscience.org/library/papers/6878096 | PubMed |
| 6,865,273 | [Non-Hodgkins's lymphomas - current aspects of clinical diagnosis and therapy]. | Klin Wochenschr | 1983 | https://conductscience.org/library/papers/6865273 | PubMed |
| 6,688,970 | A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL). | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6688970 | PubMed |
| 6,203,663 | Idiosyncratic reaction to bleomycin in an epithelial tumor. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6203663 | PubMed |
| 6,153,937 | Lung damage from cytotoxic drugs. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/6153937 | PubMed |
| 3,552,281 | N-methyl antitumour agents. A distinct class of anticancer drugs? | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3552281 | PubMed |
| 3,539,298 | Current approaches to the treatment of advanced-stage non-Hodgkin's lymphoma. | CMAJ | 1987 | https://conductscience.org/library/papers/3539298 | PubMed |
| 2,910,510 | Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2910510 | PubMed |
| 2,793,382 | Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial. | Invest New Drugs | 1989 | https://conductscience.org/library/papers/2793382 | PubMed |
| 2,471,602 | Tallysomycin S10b--a phase I trial. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2471602 | PubMed |
| 2,457,455 | HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/2457455 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/61732
GET https://conductscience.org/api/papers/v1/61732/cited_by?page=2